ONK Therapeutics
Pioneering optimally engineered NK cell therapies to cure patients with cancer.
Pioneering optimally engineered NK cell therapies to cure patients with cancer.
ONK Therapeutics is a biotechnology startup focused on pioneering optimally engineered NK cell therapies to cure patients with cancer. The company, founded in 2015 in Ireland by Prof. O’Dwyer MD, has developed a next-generation off-the-shelf, dual-targeted NK cell therapy platform targeting hematological malignancies and solid tumors.
Their core proprietary platform is based on a dual-targeted NK cell expressing both a chimeric antigen receptor (CAR) targeting a known tumor antigen and a TNF related apoptosis inducing ligand variant (TRAILv) targeting the death receptor pathway. This approach has the potential to enhance efficacy by addressing both intrinsic and extrinsic apoptotic pathways, while reducing the susceptibility to target antigen escape.
The company's groundbreaking work has attracted significant attention, leading to a recent $21.50M Series A investment on 06 January 2022 from investors including Acorn Bioventures, Cormorant Asset Management, and ALSHC.
ONK Therapeutics' innovative approach, expert leadership, and promising recent investment make it a compelling player in the biotechnology and healthcare industries, with significant potential for future growth and impact in the fight against cancer.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series A | $21.50M | 3 |
|
06 Jan 2022 |
No recent news or press coverage available for ONK Therapeutics.
We care about your data, and we'd love to use cookies make your experience better.
